News

2016
09.8

Immuneering team members co-author “Pridopidine activates neuroprotective pathways impaired in Huntington Disease”

Hum Mol Genet. 2016 Jul 27. pii: ddw238. PMID: 27466197 DOI: 10.1093/hmg/ddw238

Immuneering team members co-author “Pridopidine activates neuroprotective pathways impaired in Huntington Disease”, published in Human Molecular Genetics on July 27, 2016.


2015
09.23

Immuneering announces publication of Alzheimer’s Disease study in Scientific Reports “Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets.”

Sci Rep. 2015; 5: 14324. Published online 2015 Sep 23. doi: 10.1038/srep14324 PMCID: PMC4585817

September 23, 2015 – Immuneering is pleased to announce the publication of “Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets” in Scientific Reports, a study authored by Immuneering’s R&D team and focused on identifying new insights into this common neurodegenerative disease and new therapeutic hypotheses.


2015
08.3

Teva and Immuneering Announce Teva’s Purchase of 51% Equity Share of Genomic-Analysis Company

We are excited to work together with our colleagues at Teva to improve the lives of patients suffering from CNS diseases.


2015
05.22

Immuneering publishes “Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids” in Scientific Reports

May 22, 2015 – Immuneering is pleased to announce the publication of “Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids” in Scientific Reports, a study co-authored by R&D teams from Immuneering and Teva.


2014
01.29

Immuneering Corporation Expands Alliance with Bristol-Myers Squibb

CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ — Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (NYSE: BMY) for the use of Immuneering’s proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines.


2014
01.13

Teva and Immuneering Co-author Publication Demonstrating that Key Genes Respond Differently to COPAXONE® (glatiramer acetate injection) Versus a Purported Generic Glatiramer Acetate

Jan. 13, 2014– Teva Pharmaceuticals Industries Ltd. and Immuneering Corporation have co-authored a publication in PLOS ONE demonstrating that key genes respond differently to COPAXONE® (glatiramer acetate injection) versus a purported generic glatiramer acetate.


2013
06.2

Immuneering CEO Ben Zeskind Discusses Cancer Immunotherapy at ASCO 2013

June 2, 2013 – Immuneering CEO Ben Zeskind was interviewed during the 2013 ASCO Annual Meeting as part of a series of videos produced by the Society for Immunotherapy of Cancer (SITC), featuring experts in cancer immunotherapy.


2013
04.3

Immuneering announces the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS ONE

April 3, 2013. Cambridge, MA.  Immuneering Corporation is pleased to announce the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS ONE, with co-authors including Immuneering’s VP of Biocomputing Dr. Fadi Towfic and the co-chair of Immuneering’s scientific advisory board, Dr. Max Artyomov.


2013
02.14

Immuneering celebrates 5 years in business

Cambridge, MA.  February 14, 2013.  Today Immuneering celebrates 5 years in business.  Since the company’s founding in early 2008, Immuneering has helped many of the world’s top pharmaceutical and biotechnology companies identify actionable new insights in biological data.


2012
10.24

Immuneering CEO Ben Zeskind to speak at the 4th Translational Medicine Conference

October 25, 2012 — Immuneering’s CEO (Ben Zeskind, PhD, MBA) will moderate a plenary session at the 4th Translational Medicine Conference, and give a talk entitled Predicting Response and Understanding Mechanism: Identifying Difficult-To-Find Patterns In Biological Data.


MORE ENTRIES